Have a personal or library account? Click to login
Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor Cover

Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor

Tremor and Other Hyperkinetic Movements
Volume 15 (2025): Issue 1
By: Katherine LongardnerORCID,  Qian ShenORCID,  Francisco X. CastellanosORCID,  Bin Tang,  Rhea GandhiORCID,  Brenton A. WrightORCID,  Jeremiah D. MomperORCID and  Fatta B. NahabORCID  
Open Access
|Apr 2025

References

  1. 1Louis ED, McCreary M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor and Other Hyperkinetic Movements. 2021 Jul 9;11(1):28. DOI: 10.5334/tohm.632
    Back to article
  2. 2Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement Disorders. 2018 Jan;33(1):75–87. DOI: 10.1002/mds.27121
    Back to article
  3. 3Ferreira JJ, Mestre TA, Lyons KE, Benito-León J, Tan E, Abbruzzese G, et al. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019 Jul;34(7):950–8. DOI: 10.1002/mds.27700
    Back to article
  4. 4Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. Euro J of Neurology. 2010 Jun;17(6):882–4. DOI: 10.1111/j.1468-1331.2009.02926.x
    Back to article
  5. 5Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel ÂV, Cecilio Hallak JE, Tumas V. A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism & Related Disorders. 2021 Feb;83:37–40. DOI: 10.1016/j.parkreldis.2021.01.001
    Back to article
  6. 6Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. Montreal Cognitive Assessment [Internet]. American Psychological Association; 2014 [cited 2023 Mar 29]. Available from: http://doi.apa.org/getdoi.cfm?doi=10.1037/t27279-000.
    Back to article
  7. 7Elble R. The Essential Tremor Rating Assessment Scale. J Neurol Neuromedicine. 2016 Jul 1;1(4):34–8. DOI: 10.29245/2572.942X/2016/4.1038
    Back to article
  8. 8Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American psychiatric association; 2013.
    Back to article
  9. 9Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management. 2010 Feb;39(2):167–79. DOI: 10.1016/j.jpainsymman.2009.06.008
    Back to article
  10. 10Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial. The Journal of Pain. 2012 May;13(5):438–49. DOI: 10.1016/j.jpain.2012.01.003
    Back to article
  11. 11Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013 Apr;260(4):984–97. DOI: 10.1007/s00415-012-6739-4
    Back to article
  12. 12Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016;8(8):3448–59.
    Back to article
  13. 13Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 2018 Nov;32(11):1053–67. DOI: 10.1007/s40263-018-0578-5
    Back to article
  14. 14Silmore LH, Willmer AR, Capparelli EV, Rosania GR. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. Pharmacotherapy. 2021 Apr;41(4):405–20. DOI: 10.1002/phar.2512
    Back to article
  15. 15Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018 Nov 26;9:1365. DOI: 10.3389/fphar.2018.01365
    Back to article
  16. 16Haubenberger D, Kalowitz D, Nahab FB, Toro C, Ippolito D, Luckenbaugh DA, et al. Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord. 2011 Sep;26(11):2073–80. DOI: 10.1002/mds.23808
    Back to article
  17. 17Longardner K, Shen Q, Tang B, Wright BA, Kundu P, Nahab FB. An Algorithm for Automated Measurement of Kinetic Tremor Magnitude Using Digital Spiral Drawings. Digit Biomark. 2024;8(1):140–8. DOI: 10.1159/000539529
    Back to article
  18. 18Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service …; 1976. DOI: 10.1037/e591322011-001
    Back to article
  19. 19Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI Journal of the National Cancer Institute. 2014 Sep 29;106(9):dju244–dju244. DOI: 10.1093/jnci/dju244
    Back to article
  20. 20Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. AJP. 2011 Dec;168(12):1266–77. DOI: 10.1176/appi.ajp.2011.10111704
    Back to article
  21. 21Hubbard JA, Smith BE, Sobolesky PM, Kim S, Hoffman MA, Stone J, et al. Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 28;58(5):673–81. DOI: 10.1515/cclm-2019-0600
    Back to article
  22. 22Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018 Mar;15(3):151–66. DOI: 10.1038/nrcardio.2017.130
    Back to article
  23. 23Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009 Feb;34(3):672–80. DOI: 10.1038/npp.2008.120
    Back to article
  24. 24Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal statistical society: series B (Methodological). 1995;57(1):289–300. DOI: 10.1111/j.2517-6161.1995.tb02031.x
    Back to article
  25. 25McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, et al. Cannabis-Based Products for Chronic Pain: A Systematic Review. Ann Intern Med. 2022 Aug;175(8):1143–53. DOI: 10.7326/M21-4520
    Back to article
  26. 26Grotenhermen F. Pharmacokinetics and Pharmacodynamics of Cannabinoids: Clinical Pharmacokinetics. 2003;42(4):327–60. DOI: 10.2165/00003088-200342040-00003
    Back to article
  27. 27Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980 Sep;28(3):409–16. DOI: 10.1038/clpt.1980.181
    Back to article
  28. 28Guy GW, Robson PJ. A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112). Journal of Cannabis Therapeutics. 2004 Jan 29;3(4):79–120. DOI: 10.1300/J175v03n04_01
    Back to article
  29. 29Pressman P, Hayes AW, Hoeng J, Latino DA, Mazurov A, Schlage WK, et al. Δ9-Tetrahydrocannabinol (THC): a critical overview of recent clinical trials and suggested guidelines for future research. Journal of Clinical Medicine. 2024;13(6):1540. DOI: 10.3390/jcm13061540
    Back to article
  30. 30Patrician A, Versic-Bratincevic M, Mijacika T, Banic I, Marendic M, Sutlović D, et al. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Adv Ther. 2019 Nov;36(11):3196–210. DOI: 10.1007/s12325-019-01074-6
    Back to article
  31. 31Schuhmayer N, Weber C, Kieler M, Voller B, Pirker W, Auff E, et al. Task-dependent variability of Essential Tremor. Parkinsonism & Related Disorders. 2017 Aug;41:79–85. DOI: 10.1016/j.parkreldis.2017.05.018
    Back to article
DOI: https://doi.org/10.5334/tohm.1005 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Feb 4, 2025
Accepted on: Apr 4, 2025
Published on: Apr 14, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
essential tremor,
cannabis, therapeutics,
digital outcome measures

© 2025 Katherine Longardner, Qian Shen, Francisco X. Castellanos, Bin Tang, Rhea Gandhi, Brenton A. Wright, Jeremiah D. Momper, Fatta B. Nahab, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 15 (2025): Issue 1Next article